Headache News

Treatment with 10 mg and 20 mg of intranasal zavegepant met the primary endpoints in a randomized clinical trial — freedom from pain and the most bothersome symptom after 2 hours.

Women with menstrual migraine who were treated with galcanezumab had fewer monthly migraine headache days compared with women who received placebo, according to an analysis of three phase 3 trials.

Self-reported migraine treatment records collected via a smartphone application provided insights into migraine triggers and medication effectiveness.

One of several plenary sessions at the American Headache Society Annual Meeting, which is being held virtually, focused on sex- and gender-specific differences in headache.

Researchers observed no statistically significant differences between Ajovy and placebo for the treatment of posttraumatic headache among adults enrolled in a phase 2 study that evaluated the safety and efficacy of Ajovy.

Patients with migraine who took calcitonin gene-related peptide-targeted monoclonal antibody therapy in combination with onabotulinumtoxinA had fewer monthly headache days and less migraine-related disability, according to researchers.

Updated analyses from the phase 3, open-label STOP 301 study of nasal dihydroergotamine-based INP104 for the treatment of migraine provides new safety and tolerability data regarding nausea as well as nasal and cardiovascular outcomes.

Telemedicine enabled headache care for “many patients” during the COVID-19 pandemic, with high rates of patient satisfaction, according to findings from a survey with more than 1,000 respondents.

Fewer than 10% of patients with migraine overcome four obstacles “to good medical outcomes” according to results of the Chronic Migraine Epidemiology and Outcomes, or CaMEO, study.

A review published in The Lancet Neurology provides a summary of the classification and management of post-traumatic headache, a “disabling secondary headache disorder” often attributed to traumatic brain injury.